Pure Bioscience, Inc. (PURE) stock
PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31
$0.07−0.01 (-12.10%)
Close on Oct 19, 2026Market cap $8.67MP/E –Yield –
Pure Bioscience revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Pure Bioscience's revenue for the twelve months ending Jul 31, 2026 was $2.32M, up 5.3% year over year. For fiscal 2026 it was $2.32M, up 5.3% from the year before. Over ten years it grew 6.0% a year on average. The highest annual figure on record is $6.92M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | $2.32M | +5.3% |
| FY2025 | Jul 31, 2025 | $2.20M | +12.4% |
| FY2024 | Jul 31, 2024 | $1.96M | +4.5% |
| FY2023 | Jul 31, 2023 | $1.87M | +3.2% |
| FY2022 | Jul 31, 2022 | $1.81M | -51.0% |
| FY2021 | Jul 31, 2021 | $3.70M | -46.5% |
| FY2020 | Jul 31, 2020 | $6.92M | +262.3% |
| FY2019 | Jul 31, 2019 | $1.91M | +7.6% |
| FY2018 | Jul 31, 2018 | $1.77M | -3.1% |
| FY2017 | Jul 31, 2017 | $1.83M | +42.0% |
| FY2016 | Jul 31, 2016 | $1.29M | +76.8% |
| FY2015 | Jul 31, 2015 | $729.00K | +32.5% |
| FY2014 | Jul 31, 2014 | $550.00K | -32.9% |
| FY2013 | Jul 31, 2013 | $820.00K | +1.0% |
| FY2012 | Jul 31, 2012 | $812.00K | +75.0% |
| FY2011 | Jul 31, 2011 | $464.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jul 31, 2026 | $659.00K | -13.6% |
| Q3 FY2026CQ1 2026 | Apr 30, 2026 | $506.00K | +3.5% |
| Q2 FY2026CQ4 2025 | Jan 31, 2026 | $443.00K | +13.3% |
| Q1 FY2026CQ3 2025 | Oct 31, 2025 | $707.00K | +27.4% |
| Q4 FY2025CQ2 2025 | Jul 31, 2025 | $763.00K | +61.7% |
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | $489.00K | +11.1% |
| Q2 FY2025CQ4 2024 | Jan 31, 2025 | $391.00K | +20.3% |
| Q1 FY2025CQ3 2024 | Oct 31, 2024 | $555.00K | -22.7% |
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | $472.00K | -21.6% |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | $440.00K | +8.4% |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | $325.00K | -17.9% |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | $718.00K | +53.7% |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | $602.00K | +49.0% |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | $406.00K | -18.3% |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | $396.00K | -4.6% |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | $467.00K | -6.0% |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | $404.00K | -52.9% |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | $497.00K | -10.6% |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | $415.00K | -52.2% |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | $497.00K | -64.9% |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | $857.00K | -78.3% |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | $556.00K | -75.0% |
| Q2 FY2021CQ4 2020 | Jan 31, 2021 | $868.00K | +148.7% |
| Q1 FY2021CQ3 2020 | Oct 31, 2020 | $1.42M | +256.0% |
| Q4 FY2020CQ2 2020 | Jul 31, 2020 | $3.95M | +544.2% |
| Q3 FY2020CQ1 2020 | Apr 30, 2020 | $2.22M | +611.9% |
| Q2 FY2020CQ4 2019 | Jan 31, 2020 | $349.00K | -11.4% |
| Q1 FY2020CQ3 2019 | Oct 31, 2019 | $398.00K | -32.5% |
| Q4 FY2019CQ2 2019 | Jul 31, 2019 | $613.00K | +20.4% |
| Q3 FY2019CQ1 2019 | Apr 30, 2019 | $312.00K | -20.0% |
| Q2 FY2019CQ4 2018 | Jan 31, 2019 | $394.00K | -4.1% |
| Q1 FY2019CQ3 2018 | Oct 31, 2018 | $590.00K | +27.2% |
| Q4 FY2018CQ2 2018 | Jul 31, 2018 | $509.00K | -1.2% |
| Q3 FY2018CQ1 2018 | Apr 30, 2018 | $390.00K | +15.4% |
| Q2 FY2018CQ4 2017 | Jan 31, 2018 | $411.00K | -8.1% |
| Q1 FY2018CQ3 2017 | Oct 31, 2017 | $464.00K | -12.6% |
| Q4 FY2017CQ2 2017 | Jul 31, 2017 | $515.00K | – |
| Q3 FY2017CQ1 2017 | Apr 30, 2017 | $338.00K | – |
| Q2 FY2017CQ4 2016 | Jan 31, 2017 | $447.00K | – |
| Q1 FY2017CQ3 2016 | Oct 31, 2016 | $531.00K | – |
See a number that looks wrong?